Search - tctmd.com

Displaying 1 - 20 of 127

Sort: Relevancy | Date

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Opinion CV Team Dispatch

June 2025 Dispatch for the CV Team

L.A. McKeown

June 26, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Yael L. Maxwell

June 17, 2024

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Advertisement

September 2025 Dispatch for the CV Team

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

June 2025 Dispatch for the CV Team

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Top General Cardiology and Prevention News of 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content